Pharmacotherapy for Alcohol Use Disorder: Enhancing Health and Treatment Outcomes

Introduction and Objective: Alcohol Use Disorder (AUD) combines alcohol abuse and dependence into a single condition characterized by an inability to control alcohol consumption despite its negative consequences. Treatment for AUD includes both pharmacological and behavioral therapies aimed at achieving complete abstinence. This paper reviews pharmacological treatment options and their clinical effectiveness. Given the increasing prevalence of AUD globally, including in Poland, understanding the availability, efficacy, and cost of these treatments is essential to improve patient outcomes. Review methods: This review analyzes current literature on pharmacological treatments for AUD, including medications approved by FDA and EMA. Sources include peer-reviewed articles and clinical trials. Results: Naltrexone and nalmefene have been shown to be effective in reducing alcohol consumption and cravings, while acamprosate and topiramate are particularly effective in relapse prevention and maintaining abstinence. Gabapentin is effective in treating alcohol withdrawal symptoms, while baclofen, mifepristone, and N-acetylcysteine show promising results but require further research. Ondansetron has been documented as effective in treating young patients with early-onset AUD, and varenicline effectively reduces alcohol cravings in individuals with nicotine dependence. The disulfiram implant is ineffective in treating alcohol dependence and maintaining abstinence, with its action primarily based on the fear of a disulfiram reaction. Conclusions: Pharmacological treatments for AUD, combined with behavioral therapy, help reduce alcohol consumption or maintain abstinence. Individualized therapy selection is crucial, taking into account the patient's health status and the presence of other conditions. Further research is required to optimize treatment, both in terms of pharmacological mechanisms and better tailoring the therapy to the specific needs of individual patients.

Authors

Publication Details

Journal
Quality in Sport
Published
2025-03-05
DOI
https://doi.org/10.12775/qs.2025.39.58999
Primary Topic
Pharmaceutical Practices and Patient Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Pharmacotherapy for Alcohol Use Disorder: Enhancing Health and Treatment Outcomes

Marta Malicka, Agnieszka Kozioł, Maria Jasiewicz, Patrycja Karnas-Bogacka et al.
Quality in Sport
Pharmaceutical Practices and Patient Outcomes
article

Pharmacotherapy for Alcohol Use Disorder: Enhancing Health and Treatment Outcomes

Marta Malicka, Agnieszka Kozioł, Maria Jasiewicz, Patrycja Karnas-Bogacka, Katarzyna Moczyróg, Piotr Mól, Aleksandra Sierpińska, Agata Jaksz
article en

Abstract

Introduction and Objective: Alcohol Use Disorder (AUD) combines alcohol abuse and dependence into a single condition characterized by an inability to control alcohol consumption despite its negative consequences. Treatment for AUD includes both pharmacological and behavioral therapies aimed at achieving complete abstinence. This paper reviews pharmacological treatment options and their clinical effectiveness. Given the increasing prevalence of AUD globally, including in Poland, understanding the availability, efficacy, and cost of these treatments is essential to improve patient outcomes. Review methods: This review analyzes current literature on pharmacological treatments for AUD, including medications approved by FDA and EMA. Sources include peer-reviewed articles and clinical trials. Results: Naltrexone and nalmefene have been shown to be effective in reducing alcohol consumption and cravings, while acamprosate and topiramate are particularly effective in relapse prevention and maintaining abstinence. Gabapentin is effective in treating alcohol withdrawal symptoms, while baclofen, mifepristone, and N-acetylcysteine show promising results but require further research. Ondansetron has been documented as effective in treating young patients with early-onset AUD, and varenicline effectively reduces alcohol cravings in individuals with nicotine dependence. The disulfiram implant is ineffective in treating alcohol dependence and maintaining abstinence, with its action primarily based on the fear of a disulfiram reaction. Conclusions: Pharmacological treatments for AUD, combined with behavioral therapy, help reduce alcohol consumption or maintain abstinence. Individualized therapy selection is crucial, taking into account the patient's health status and the presence of other conditions. Further research is required to optimize treatment, both in terms of pharmacological mechanisms and better tailoring the therapy to the specific needs of individual patients.

Quality in SportVol. 39
Openalex Percentile: Top 95%
Pharmaceutical Practices and Patient Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.